Supplementary Table 2 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
posted on 2023-03-31, 20:08authored byGeoffrey Liu, Sinead Cuffe, Shermi Liang, Abul Kalam Azad, Lu Cheng, Yonathan Brhane, Xin Qiu, David W. Cescon, Jeffrey Bruce, Zhuo Chen, Dangxiao Cheng, Devalben Patel, Brandon C. Tse, Scott A. Laurie, Glenwood Goss, Natasha B. Leighl, Rayjean Hung, Penelope A. Bradbury, Lesley Seymour, Frances A. Shepherd, Ming Sound Tsao, Bingshu E. Chen, Wei Xu, David N. Reisman
Subgroup prognostic analyses of BRM polymorphisms in adjusted Hazard ratios (95% confidence intervals) - each comparison uses wildtype or double wildtype as the reference category.